Compare RBBN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | PRTA |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 539.9M |
| IPO Year | 2017 | 2013 |
| Metric | RBBN | PRTA |
|---|---|---|
| Price | $2.78 | $10.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $4.67 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.0M | 342.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $1.97 | $1,111.38 |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $4.32 |
| 52 Week High | $4.29 | $11.69 |
| Indicator | RBBN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 52.77 |
| Support Level | $2.72 | $9.81 |
| Resistance Level | $2.93 | $11.61 |
| Average True Range (ATR) | 0.17 | 0.51 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 58.93 | 25.71 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.